The administration of AMD improved the impairment of cardiac function and alleviated the cardiac hypertrophy indicators, such as ventricular mass/body weight, myocyte cross-sectional area, and the expression of ANP, BNP, and Myh7, in the transverse aortic constriction (TAC) induced cardiac hypertrophy model. This evidence concerns the gene NPPA and cardiac hypertrophy.